Amyotrophic lateral sclerosis: recent advances and future therapies.
OBJECTIVE
Amyotrophic lateral sclerosis is a rare but fatal motoneuron disorder. Despite intensive research riluzole remains the only available therapy, with only marginal effects on survival. Here we review some of the recent advances in the search for a disease-modifying therapy for amyotrophic lateral sclerosis.


RESULTS
A number of established agents have recently been re-investigated for their potential as neuroprotective agents, including beta-lactam antibiotics and minocycline. Progress has also been made in exploiting growth factors for the treatment of amyotrophic lateral sclerosis, partly due to advances in developing effective delivery systems to the central nervous system. A number of new therapies have also been identified, including a novel class of compounds, heat-shock protein co-inducers, which upregulate cell stress responses thereby mediating neuroprotection. Non-drug-based therapies are also under development, with progress in gene-silencing and stem cell therapies.


CONCLUSIONS
In the past few years, significant advances have been made in both our understanding of amyotrophic lateral sclerosis pathogenesis and the development of new therapeutic approaches. However, caution must be exercised in view of the long-standing failure to successfully transfer therapeutic compounds to the clinic. A deeper awareness in the research community of the need for clinically relevant preclinical studies, coupled with a better understanding of the issues surrounding clinical trial design for amyotrophic lateral sclerosis, offers hope that the growing list of validated preclinical therapeutics can finally yield an effective disease-modifying treatment.
Nirmalananthan
Niranjanan
N
Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery, London, UK.
Greensmith
Linda
L
D000690:Amyotrophic Lateral Sclerosis / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D000818:Animals; D035843:Biomedical Research; D004281:Docosahexaenoic Acids / Q000145:classification / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D005544:Forecasting; D006801:Humans
D004281:Docosahexaenoic Acids